BioSyntech Inc.
TSX VENTURE : BSY

BioSyntech Inc.

May 25, 2006 07:00 ET

Biosyntech Appoints New Board Member

LAVAL, QUEBEC--(CCNMatthews - May 25, 2006) - BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX VENTURE:BSY) today announced the appointment of Rudy Huber to its board of directors. Mr. Huber is the representative for an institution that invested in the Company's recent financing.

Rudy Huber has more than 25 years of business experience in the health care industry in Canada, with a focus on the dental market. He has held various sales and marketing positions for international companies including Johnson and Johnson. He is also an entrepreneur and co-owner of a successful Canadian distributor for a leading manufacturer of dental implant components and related components, 3i Implant Innovations Inc, a subsidiary of 3i Implant Innovations Inc. a Biomet company (NASDAQ:BMET). Since 1999, Mr. Huber has been the Country Manager for 3i Implant Innovations Canada, responsible for both the strategic and operational activities of the company. He has also served on boards of medical device companies including Cryocath (CYT.TO). Mr. Huber has a Bachelor of Commerce from Concordia University in Montreal.

"It is a pleasure to welcome Mr. Huber to our board of directors," stated Joseph Benarrosh, Chairman of the Board of BioSyntech. "His experience in the commercialization of medical devices and the success he has achieved in his career are major assets for BioSyntech. His arrival will benefit the Company's development at a crucial period where we are advancing our innovative products to the market."

The board of directors has approved the granting of 330,000 options to two officers of the Company under the Company's stock option plan, at an exercise price of $0.48 per share for a period of 5 years.

About BioSyntech

BioSyntech is a biotechnology company specializing in the discovery, development and manufacturing of innovative, cost-effective, and physician-friendly biotherapeutic thermogels for regenerative medicine and therapeutic delivery. BioSyntech's Quality Management System is registered to ISO 9001:2000 standard. For additional information, visit www.biosyntech.com.

Forward Looking Statements

This press release contains forward-looking statements and information which are subject to material risks and uncertainties. Such statements are not historical facts and are based on the current expectations of management. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the potential dilutive effects of any financing, the adequacy, timing, and results or our clinical trials, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, the success of research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to-time in our filings with the Canadian securities commissions.

Readers should not place undue reliance on the forward-looking information, given that (i) our actual results could differ materially from a conclusion, forecast or projection in the forward-looking information, and (ii) certain material factors or assumptions which were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, could prove to be inaccurate. Additional information about (i) the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information, and (ii) the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, is contained in the Company's annual report and other documents filed from time to time with the Canadian securities commissions which are available at www.sedar.com.

Any statements that are contained in this analysis that are not statements of historical facts may be deemed to be forward looking statements made pursuant to the safe harbour provisions of the Private Securities Litigation Reformation Act of 1995. Without limiting the foregoing, the words "believe", "anticipates", "plans", "estimates", intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward looking statements.

These statements speak only as of the date they are made, and we assume no obligation to revise such statements as a result of any event, circumstance or otherwise, except in accordance with law.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information

  • BioSyntech, Inc.
    Claude LeDuc
    President and CEO
    (450) 686-2437, ext. 233
    or
    The Equicom Group Inc.
    Francois Kalos
    (514) 844-6054
    fkalos@equicomgroup.com